生理药代动力学模型预测利福布汀治疗幽门螺杆菌感染的胃内浓度
本研究利用经RHB-105临床开发项目血浆药代动力学数据验证的全身生理药代动力学模型,比较低剂量利福布汀(50 mg每日三次)与150 mg每日一次、150 mg每日两次及300 mg每日一次方案的胃内暴露。结果显示50 mg每日三次方案胃内浓度≥MIC90的时间显著长于其他方案,且全身暴露最低。
要点
- 利福布汀50 mg每日三次的胃内浓度≥MIC90时间显著长于其他给药方案。
- 该低剂量方案在研究的各方案中全身平均最大血浆浓度和平均药时曲线下面积最低。
- 低剂量利福布汀方案在根除幽门螺杆菌的同时可最小化全身利福布汀暴露。
核心结论
- 生理药代动力学模型显示,利福布汀50 mg每日三次的胃内暴露时间高于150 mg每日一次、150 mg每日两次或300 mg每日一次。
- 该低剂量利福布汀方案在根除幽门螺杆菌方面潜力最高,同时最小化全身利福布汀暴露。
研究设计与样本
- 利用RHB-105临床开发项目的血浆药代动力学数据,使用PK-SIM软件开发并验证全身生理药代动力学模型。
- 修改现有利福布汀模型以纳入奥美拉唑对胃内pH和排空时间的影响。
- 以各方案维持胃内浓度≥MIC90的时间作为模型化胃内利福布汀暴露的指标。
主要发现
- 利福布汀50 mg每日三次的胃内浓度≥MIC90时间为22.3 ± 1.1 h,显著长于150 mg每日一次(8.3 ± 1.7 h)、150 mg每日两次(16.3 ± 2.3 h)或300 mg每日一次(8.5 ± 1.9 h)。
- 利福布汀50 mg每日三次在所有研究方案中提供最低的平均最大血浆浓度和平均药时曲线下面积。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sustained intragastric antibiotic exposure is important for Helicobacter pylori eradication, yet little is known about gastric pharmacology of commonly used H. pylori regimens. For rifabutin, differing intragastric concentrations based on dosing regimen may account for differences in reported eradication rates. AIM: To compare intragastric rifabutin concentrations between low-dose rifabutin (50 mg three time daily; as in RHB-105) and generically dosed rifabutin 150 mg once daily, 150 mg twice daily, and 300 mg once daily using a validated Physiologically-based pharmacokinetic (PBPK) model. METHODS: We obtained plasma pharmacokinetic data from the RHB-105 clinical development programs and used it to develop and validate a whole-body PBPK model using PK-SIM software. We modified the existing rifabutin model to include the impact of omeprazole on gastric pH and emptying time. Modelled intragastric rifabutin exposure was expressed as the time that each regimen maintained its concentration ≥MIC90 . RESULTS: Rifabutin 50 mg three times daily achieved significantly longer times with intragastric concentration above MIC90 (22.3 ± 1.1 h) than 150 mg once daily (8.3 ± 1.7 h), 150 mg twice daily (16.3 ± 2.3 h), or 300 mg once daily (8.5 ± 1.9 h) while providing the lowest mean maximal plasma concentration and mean area under the plasma concentration-time curve of all regimens studied. CONCLUSIONS: PBPK modelling showed rifabutin 50 mg three times daily had higher intragastric exposure times than 150 mg once daily or twice daily, or 300 mg once daily. This low-dose rifabutin regimen provides the highest potential for H. pylori eradication while minimising systemic rifabutin exposure.
引用
- Howden CW, Shah S, Pendse SN, et al. Physiologically-based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2023. PMID: 37081832. doi:10.1111/apt.17526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。